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In India, BDQ is in use since 2016 for the treatment of MDR-TB and XDR-TB under the conditional access program of Revised National TB Control Program. [5] In the current WHO DRTB treatment guidelines, [6] the use of BDQ is prioritized over other drugs, especially injectables for the treatment of DRTB. With this, the use of BDQ is likely to be multiple times higher. However, information on existing or emerging resistance to BDQ is currently very limited as a clear guideline on a standard drug-susceptibility testing (DST) method is awaited. Few premier reference laboratories have adopted different methodologies, including the minimum inhibitory concentration (MIC) using solid Middlebrook 7H11 medium or Middlebrook 7H9 liquid broth-based methods. [7] DST at a critical concentration of 1 mg/L using the commercial BACTEC MGIT960 liquid culture system has been recently recommended by the WHO. [8] DST to BDQ with a single concentration of the drug using MGIT960 system earlier was hampered due to adsorption of the drug to the polypropylene plastic tubes. [9] With the recent introduction of polystyrene tubes by the manufacturer, this issue has been resolved.
In the present study, validation following the standard protocol described in the current GCLP guidelines [10] for BDQ DST by BACTEC MGIT 960 was carried out.
Methods

Setting
The present study was carried out at the NABL accredited ICMR-National Institute for Research in Tuberculosis, Chennai, a Supranational Reference Laboratory under WHO and National Reference Laboratory under the Revised National Tuberculosis Control Program of India. This validation was done as part of continued efforts toward capacity building of the laboratory to be on par with international laboratories to meet crucial demands for TB control.
Ethical statement
As the study neither involve human clinical specimens nor clinical isolates, ethical clearance was not necessary.
Bedaquiline drug
The pure form of BDQ drug with 100% purity was a kind gift from Cipla Pharmaceuticals, Mumbai, India.
Mycobacterium tuberculosis strains
A panel of ten M. tuberculosis isolates comprising 8 BDQ susceptible and 2 BDQ-resistant strains were used for the study. All the strains were obtained from the Institute of Tropical Medicine (ITM), Antwerp, Belgium. MIC protocol in Middlebrook 7H11 method using polystyrene tubes [7] approved by EUCAST was used as the gold standard. [11] Only one BDQ-resistant strain was received and the same was duplicated. All isolates were coded for each validation parameter, and the results were compared after decoding.
Drug stock preparation
Drug stock was prepared at par with WHO recommended concentration. [8] Accordingly, 1 µg/mL concentration was prepared from the lyophilized BDQ powder using the following formula. Three stocks of 1 ml each were prepared.
Weight (mg) = Volume (mL) × Concentration (µg/mL) × dilution factor/assay potency (µg/mg) • Volume (in milliliters) is the desired volume of stock solution • Concentration (micrograms per milliliter) is the desired concentration of stock solution • Dilution factor is the number of times the drug added to the tube (100 µl) is getting diluted by the total volume of the medium in the tube (8.3 ml) = 83 • Assay potency (micrograms per milligram) is the activity or potency specified by the manufacturer of the reference standard powder. This value usually appears on the label or the certificate of analysis • Weight (milligrams) is the weight of powder needed to prepare the desired volume of stock solution at the desired concentration.
Accordingly weight (mg) =1 × 1 × 83/1000 = 0.083 mg.
As it was difficult to weigh 0.083 mg, 100 times the weight, i.e., 8.3 mg was weighed and dissolved in 1 ml of dimethyl sulphoxide. The stocks were aliquoted at 120 µl each and stored at −80°C. At the time of MGIT DST, the stock was diluted 1:100 (100 µl of stock + 9.9 ml sterile DW) to get the desired working stock.
BACTEC MGIT 960
The isolates were freshly sub-cultured and DST was done at 1 µg/ml using the manufacturer's protocol for "undefined drug." The duration of the protocol is 3-13 days. Table 2 ].
Validation parameters Accuracy
Reproducibility
The results of BDQDST by MGIT 960 performed by two technologists on 3 days using 3 different batches of drug stocks demonstrated 100% reproducibility between the users and days and between the batches [ Table 3 ]. However, the growth unit of MGIT showed mild variations but was well within the cutoff.
dIscussIon
Treatment of DRTB till recently comprised less effective but more toxic drugs for prolonged durations. BDQ has been in have been reported earlier. A presumptive MIC of 0.25 mg/L for Middlebrook 7H11 and rezazurin microtiter assay (REMA) was suggested by (ITM: Antwerp, Belgium) and MIC of 1 mg/L was reported for MGIT960. [7] However, reports on BDQ DST using a single concentration are scarce.
Against a background of scarce reports on BDQ DST using a single concentration of the drug, the current work is the first report from India on the validation and feasibility of a much-needed protocol on BDQ DST by BACTEC MGIT 960. The commercial liquid culture-based system is currently considered the gold standard for phenotypic DST due to its rapidity, reliability, and reproducibility and can be subjected to quality assurance protocols. Evidence on the feasibility of a standard methodology on BDQ DST would expand the scope of DST-guided treatment for drug-resistant TB patients.
conclusIon
Bedaquiline drug susceptibility testing using BACTEC MGIT960 system has been successfully validated and may be adopted for use with clinical isolates of Mycobacterium tuberculosis.
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references use in national TB control programs with conditional access. [5] Being an oral drug with less toxic side effects, the WHO in its recent recommendations has prioritized BDQ over other injectables for the treatment of DRTB. [6] Any DST not only guides treatment but also forms the tool for monitoring the emergence of drug resistance through surveillance studies. With the anticipated widespread use of BDQ, availability of a standard method of DST for BDQ becomes paramount, especially in a country like India with high-DRTB burden. With cross resistance between clofazimine and BDQ being reported, [12] it is all the more important to establish a standard DST methodology for BDQ independently.
While stressing the need for developing an accurate and reliable DST method for BDQ, the WHO had earlier recommended the MIC method. BDQ DST by MIC using Middlebrook 7H11 agar and BACTEC MGIT960 [7] and Middlebrook 7H9 broth [13] 
